Integrated DNA Technologies✓

Are you in Hamburg for #ESGCT? Come visit us! We’re at booth #C-03 ready to discuss how our gene editing solutions are helping researchers move discoveries forward with confidence. 🪧Reminder: Visit our poster presentation on multiplexed empirical off-target nomination on October 29 from 2:00-4:00, #P0922

As #geneediting advances, comprehensive #off-target detection is becoming increasingly important for guide RNA selection, risk assessment, and therapeutic development. Recent research published in @Nature demonstrated that IDT's UNCOVERseq™ achieved the strongest combined sensitivity and precision among the approaches evaluated, helping identify validated off-target sites that other methods may miss. Learn more from IDT's Gavin Kurgan:

You’ve finalized a construct, submitted it for synthesis, and learned it may be difficult to manufacture. That can be frustrating, but it does not always mean starting over! Our guide can help you identify the likely cause and choose a practical path forward. Read it here:

#ASHG2026 is underway in Montréal! Remember to stop by booth #1216 to meet the IDT team and explore flexible, end-to-end genomics solutions supporting cancer research, translational studies, and biomarker discovery. We'd love to hear about your research and discuss how we can move it from sample to insight. 🧬✨

Counting down the days to #ESGCT2026! There’s a few ways to see us: 🧬Join IDT trusted experts at booth #C-03 to see how we’re advancing the future of cell and gene therapy through precision genome editing. 🪧Visit our poster presentation on multiplexed empirical off-target nomination. Date and time below. From guide RNA design and off-target assessment to translational and GMP-ready solutions, we're helping researchers move discoveries forward with confidence. Learn more:

Today on #WorldCRISPRDay, we're celebrating a technology that continues to redefine what's possible in medicine. From advancing our understanding of disease, to enabling precise therapeutic approaches, CRISPR is helping unlock new possibilities for patients facing some of the rarest and most challenging genetic conditions. The story of Baby KJ, who received the world's first personalized mRNA-based #CRISPRtherapy, offers a powerful view of that future. It also highlights how gene editing, RNA manufacturing, and delivery technologies are converging into connected therapeutic workflows that could make personalized genetic medicines faster, more reproducible, and more scalable. For IDT, this work reflects a commitment to advancing the technologies, expertise, and infrastructure needed to support the next generation of CRISPR-enabled therapies. We're proud to have contributed to this groundbreaking effort and to continue working alongside the scientific community to help accelerate innovation from discovery through development. Read our latest article with @Nature featuring IDT’s Ashely Jacobi and @aldevron's Cory Smith here:

IDT+@AnsaBio enables sequences traditional synthesis never intended to make—now with a 42x increase in complexity threshold and constructs up to 50 kb available through online ordering. Imagine ordering the sequence your science actually demands! Learn more here:

In collaboration with @todaysclinical, we've developed a new educational guide exploring the fundamentals of MRD and MCED research, including key applications, workflow considerations, and analytical challenges. Download the guide to learn how researchers are leveraging #NGS and #liquidbiopsy approaches to advance #MRD and #MCED research:

Festival of Biologics is in full swing! Remember to stop by booth #360 to discover how we're helping researchers accelerate breakthroughs with synthetic biology, NGS, and advanced genomics solutions. See you soon! 👋

We have two posters presentations at #ASHG2026! Join us on Thursday and Friday to learn more about our xGen™ exome panels in action. You won’t want to miss these. Details below! Learn more here:

As #MRD and #MCED research continue to expand #oncology genomics, preserving and converting rare molecular signals is becoming increasingly important for generating high-quality sequencing data in research applications. Read more from IDT's Scott McCuine here: #NGS #oncologyresearch #cancerresearch

RT @agbt: 🧬 Meet the 2027 AGBT General Meeting Major Sponsors! @illumina, @Roche, @idtdna, @UltimaGenomics, @NEBiolabs, @bruker, @CompleteGenomic, @nanopore, Syndex Bio, @WatchmakerGeno1, @WatersCorp, and @ElemBio. 📅 March 1–4 | Orlando, FL: #AGBTGM27 #Sponsors

🔥Tomorrow is the last day to take advantage of free IDT products for your @iGEM project!🔥 We offer up to 40kb of gBlocks™ Gene Fragments or equivalent value of IDT products to registered teams. Hurry and grab your supplies before the deadline closes:

Meet us in Montréal for #ASHG2026! Stop by booth #1216 to connect with IDT’s trusted experts and learn how our flexible, end-to-end genomics solutions support #cancerresearch, translational studies, and #biomarkerdiscovery from sample to insight. Learn more here:

Meet us at Festival of Biologics! Stop by booth #360 to discover how we're helping researchers accelerate breakthroughs with synthetic biology, NGS, and advanced genomics solutions. From therapeutic discovery and cell engineering to biomarker identification and translational research, our technologies enable scientists to move faster from hypothesis to insight. Learn more and schedule a meeting here:

As #AI transforms what's possible in biology, staying ahead of emerging risks is critical. See how IDT and industry collaborators are strengthening #DNAscreening to help protect the #bioeconomy while enabling scientific innovation. Read insights from IDT's Adam Clore and other leaders in @GenomeWeb:

🎗Reminder to the @iGEM community: it’s not too late to order! The last day to order from IDT is October 12. Be sure to check out the free resources we offer to help accelerate your project here:

Avoid dead-end workflows when your fragment request hits a limit. With IDT and @AnsaBio, there’s a better path forward. ⏩ Our “No Loose Ends” workflow helps guide complex designs beyond fragment fit—toward fully assembled clonal genes, without losing momentum. 🧬 So when your project gets more ambitious, your workflow doesn’t stall. Learn more here: